Evidence map›Paper›PMID 37498951›Full record

ArticlePloS one2023

Antimicrobial resistance landscape and COVID-19 impact in Egypt, Iraq, Jordan, and Lebanon: A survey-based study and expert opinion.

Abdul Rahman Bizri, Alia Abd El-Fattah, Hafez Mahmoud Bazaraa, Jamal Wadi Al Ramahi, Madonna Matar, Rana Abdulmahdi Nahi Ali, Rowan El Masry, Jihane Moussa, Ali Jamal Al Abbas, Mohamed Abdel Aziz

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Leaf Extracts ofTheScientificWorldJournal · 2024
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Abdul Rahman BizriNational COVID-19 Vaccine Committee, American University of Beirut Medical Center, Beirut, Lebanon.
Alia Abd El-FattahCritical Care Department, Cairo University, Giza, Egypt.
Hafez Mahmoud BazaraaPediatric Critical Care Units, Department of Pediatrics, Faculty of Medicine, Cairo University, Giza, Egypt.
Jamal Wadi Al RamahiSchool of Medicine, University of Jordan, Amman, Jordan.ORCID 0000-0003-2242-6232
Madonna MatarNotre Dame des Secours University Hospital, Byblos, Lebanon.ORCID 0000-0003-4870-8879
Rana Abdulmahdi Nahi AliPublic Health Directorate, Ministry of Health, Baghdad, Iraq.
Rowan El MasryMedical Affairs, Pfizer, Egypt.
Jihane MoussaPfizer Inc, Medical Affairs, Lebanon.
Ali Jamal Al AbbasMedical Affairs, Pfizer, Iraq.
Mohamed Abdel AzizPfizer Inc, Medical Affairs, United Arab Emirates.
Cairo University · EGAmerican University of Beirut Medical Center · LBBaghdad Medical City · IQHoly Spirit University of Kaslik · LBMinistry of Health · IQUniversity of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe objective of this study was to assess the antimicrobial resistance (AMR) landscape and the impact of COVID-19 on AMR in Egypt, Iraq, Jordan, and Lebanon, and to gather expert opinions on the barriers to the implementation of antimicrobial stewardship (AMS) initiatives in the region.

methodsA cross-sectional questionnaire survey was used to assess the current AMR landscape, existing AMS initiatives, barriers to implementing AMS initiatives, and the impact of COVID-19 on AMR in the four countries.

resultsThe survey was completed by 204 physicians from Egypt (n = 82), Lebanon (n = 49), Iraq (n = 43), and Jordan (n = 30). Previous antibiotic use and previous bacterial colonization were perceived as the most common risk factors for an increase in AMR. According to the survey, multidrug-resistant (MDR) gram-negative bacteria were most common in lower respiratory tract infections, and Klebsiella pneumoniae and Escherichia coli were the most commonly identified gram-negative bacteria in hospital-acquired infections. Only 14.8% of pediatric physicians and 28.6% of adult physicians reported that target pathogen genotyping and phenotyping were done in hospitals, and the most commonly reported reasons for the lack of testing were technological and resource constraints. These constraints, coupled with the scarcity and high cost of newer antibiotics, have been identified as the most significant barriers to the successful management of MDR gram-negative bacterial infections in the region. It was reported that the spectrum of activity and safety of the antibiotic, the site of infection, the presence of comorbidities, and published guidelines and local antibiograms determined the choice of empirical antibiotic therapy for patients in the region. The four countries experienced a significant rise in AMR due to several factors during the COVID-19 pandemic, including an increase in hospital occupancy, a shift in priorities away from AMR surveillance, and changes in AMR epidemiology. Additionally, the large volumes of unnecessary and unsubstantiated antibiotic prescriptions during the COVID-19 pandemic has led to subsequent antibiotic shortages and significant increases in AMR in the region. Physicians also noted that the majority of COVID-19 patients were already on antibiotics before visiting the healthcare facility. MDR gram-negative bacteria were found in the majority of COVID-19 patients admitted to the intensive care unit. Despite the fact that various AMS initiatives have been implemented, they are not standardized across the region. Some of the main barriers to AMS implementation in the region are a lack of adequately trained AMS staff, lack of AMS knowledge and training among healthcare professionals, financial constraints, and the lack of AMR surveillance systems.

conclusionThese survey results provide valuable insights into the existing AMR and AMS landscape in the region, as well as the barriers that impede efficient AMS and AMR management. Based on these findings, the authors developed a call to action that suggests ways for each country in the region to address these challenges.

Indexed as

Anti-Bacterial AgentsCOVID-19AdultChildCross-Sectional StudiesDrug Resistance, BacterialEgyptHumansIraqJordanLebanonPandemicsSurveys and QuestionnairesAnti-Bacterial Agents

Identifiers

PMID37498951
PMCPMC10374138
OpenAlexW4385325790

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.